Registration successful
Account activated – pending validation.
Your account has been activated successfully, but we still need to validate you as a healthcare professional. We’ll send you an email with the result of the validation process in the next three days.
In the meantime, you can enjoy access to all the latest news, events and resources for different therapy areas on our website.
Open
Slide the cover down until you hear a click. The dose counter counts down by 1, and you’re ready to take one dose of your medicine
TRELEGY Ellipta: Not all COPD treatments are the same
Video player requires JavaScript enabled. You can download this video here: https://videos.gskstatic.com/pharma/GSKpro/SaudiArabia/MP4/ers_2019_asset_9_trelegy_mtd_video_molecule_updated_sa_2020.mp4https://videos.gskstatic.com/pharma/GSKpro/SaudiArabia/WEBM/ers_2019_asset_9_trelegy_mtd_video_molecule_updated_sa_2020.webmhttps://videos.gskstatic.com/pharma/GSKpro/SaudiArabia/OGV/ers_2019_asset_9_trelegy_mtd_video_molecule_updated_sa_2020.ogv
TRELEGY Ellipta was intentionally designed to provide your COPD patients with sustained efficacy from today, so they can expect more from tomorrow.1-3
Designed for sustained lung function improvement over 24 hours, from just one dose
Adapted from Lipson et al. 2017 4
First doses of TRELEGY Ellipta and Symbicort Turbuhaler given at 0h; second dose of Symbicort Turbuhaler given ~12h later
*MCID: Minimal clinically important difference. Patients with COPD have been shown to perceive an improvement of ≥100 mL
in trough FEV₁ as beneficial 5
Not all COPD inhalers are the same
4.6x fewer patients
made a critical error* with Ellipta vs. MDI
(Ellipta 13%; MDI 60%, p<0.001) 7
Single-visit, placebo inhaler, crossover comparison in patients naïve to Ellipta and the comparator inhaler (p<0.001 for all comparisons) 7
Adapted from van der Palen et al. 2016 7
*Defined as errors that are likely to result in no, or minimal, medication being delivered to the lungs 7
**This study assessed critical errors in the most common type of MDI (metered–dose inhaler) where shaking prior to use is required. The most common critical error with an MDI was poor actuation and inhalation coordination 7
8.8x fewer patients
made a critical error* with Ellipta vs. Accuhaler
(Ellipta 5%; Accuhaler 44%, p<0.001) 7
Single-visit, placebo inhaler, crossover comparison in patients naïve to Ellipta and the comparator inhaler (p<0.001 for all comparisons) 7
Adapted from van der Palen et al. 2016 7
*Defined as errors that are likely to result in no, or minimal, medication being delivered to the lungs 7
5.5x fewer patients
made a critical error* with Ellipta vs. Turbuhaler
(Ellipta 8%; Turbuhaler 44%, p<0.001) 7
Single-visit, placebo inhaler, crossover comparison in patients naïve to Ellipta and the comparator inhaler (p<0.001 for all comparisons) 7
Adapted from van der Palen et al. 2016 7
*Defined as errors that are likely to result in no, or minimal, medication being delivered to the lungs 7
3.4x fewer patients
made a critical error* with Ellipta vs. Handihaler
(Ellipta 14%; Handihaler 48%, p<0.001) 7
Single-visit, placebo inhaler, crossover comparison in patients naïve to Ellipta and the comparator inhaler (p<0.001 for all comparisons) 7
Adapted from van der Palen et al. 2016 7
*Defined as errors that are likely to result in no, or minimal, medication being delivered to the lungs 7
3.5x fewer patients
made a critical error* with Ellipta vs. Breezhaler
(Ellipta 13%; Breezhaler 46%, p<0.001) 7
Single-visit, placebo inhaler, crossover comparison in patients naïve to Ellipta and the comparator inhaler (p<0.001 for all comparisons) 7
Adapted from van der Palen et al. 2016 7
*Defined as errors that are likely to result in no, or minimal, medication being delivered to the lungs 7
-
MDI 4.6x fewer patients
made a critical error* with Ellipta vs. MDI
(Ellipta 13%; MDI 60%, p<0.001)10Single-visit, placebo inhaler, crossover comparison in patients naïve to Ellipta and the comparator inhaler (p<0.001 for all comparisons)¹⁰
Adapted from van der Palen et al. 201610*Defined as errors that are likely to result in no, or minimal, medication being delivered to the lungs10
**This study assessed critical errors in the most common type of MDI (metered–dose inhaler) where shaking prior to use is required. The most common critical error with an MDI was poor actuation and inhalation coordination10
-
ACCUHALER 8.8x fewer patients
made a critical error* with Ellipta vs. Accuhaler
(Ellipta 5%; Accuhaler 44%, p<0.001)10Single-visit, placebo inhaler, crossover comparison in patients naïve to Ellipta and the comparator inhaler (p<0.001 for all comparisons)10
Adapted from van der Palen et al. 201610*Defined as errors that are likely to result in no, or minimal, medication being delivered to the lungs10
-
TURBUHALER 5.5x fewer patients
made a critical error* with Ellipta vs. Turbuhaler
(Ellipta 8%; Turbuhaler 44%, p<0.001)10Single-visit, placebo inhaler, crossover comparison in patients naïve to Ellipta and the comparator inhaler (p<0.001 for all comparisons)10
Adapted from van der Palen et al. 201610*Defined as errors that are likely to result in no, or minimal, medication being delivered to the lungs10
-
HANDIHALER 3.4x fewer patients
made a critical error* with Ellipta vs. Handihaler
(Ellipta 14%; Handihaler 48%, p<0.001)10Single-visit, placebo inhaler, crossover comparison in patients naïve to Ellipta and the comparator inhaler (p<0.001 for all comparisons)10
Adapted from van der Palen et al. 201610*Defined as errors that are likely to result in no, or minimal, medication being delivered to the lungs10
-
BREEZHALER 3.5x fewer patients
made a critical error* with Ellipta vs. Breezhaler
(Ellipta 13%; Breezhaler 46%, p<0.001)10Single-visit, placebo inhaler, crossover comparison in patients naïve to Ellipta and the comparator inhaler (p<0.001 for all comparisons)10
Adapted from van der Palen et al. 201610*Defined as errors that are likely to result in no, or minimal, medication being delivered to the lungs10
TRELEGY Ellipta quick links
Need help with this product?
Footnotes
FEV₁, forced expiratory volume in one second; ICS, inhaled corticosteroid; LABA, long-acting β₂-agonist; LAMA, long-acting muscarinic antagonist; MDI, metered-dose inhaler; OD, once daily; QoL, quality of life
TRELEGY Ellipta OD is indicated for maintenance treatment in adult patients with moderate-to-severe chronic obstructive pulmonary disease (COPD) who are not adequately treated by a combination of an ICS and a LABA 1
References
- Trelegy Local prescribing information based on EMEA V 1.
- Lipson DA et al. Am J Crit Care Med 2017; 196:438–446.
- Lipson DA et al. N Engl J Med 2018; 378:1671–1680.
- Lipson DA et al. Poster presented at ATS 2017; Poster 372 (A3605).
- Jones PW et al. Am J Respir Crit Care Med 2014; 189:250–255.
- Riley JH et al. Int J Chron Obstruct Pulm Dis 2016; 11:1873–1880.
- van der Palen J et al. NPJ Prim Care Respir Med 2016; 26:16079.
- TRELEGY Ellipta Patient Information Leaflet, 2019.
© 2020 GSK Group of Companies or its licensor
Trademarks are the property of their respective owners
TRELEGY Ellipta was developed in collaboration with
PM-SA-FVU-WCNT-200012 Date of preparation: September 2020
